ART Advanced Research Technologies Inc. (“ART”) (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that it has obtained authorization from Health Canada’s Therapeutic Products Directorate to begin a pilot study to evaluate the effectiveness of the SoftScan optical breast imaging system in treatment monitoring. Dr. Gregory Czarnota, Radiation Oncologist at the Sunnybrook Health Sciences Centre in Toronto, Canada, will lead the study, which is expected to extend the clinical value of SoftScan beyond its important role in breast cancer detection and diagnosis and into breast cancer treatment.
